ArticleScientific data2026
A histopathologically verified dataset of magnifying narrow-band imaging endoscopy for classifying the gastric precancerous cascade.
Article in Scientific data, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Gastric cancer is a leading cause of mortality worldwide, yet the development of computer-aided diagnosis (CAD) systems for its early detection is hindered by the scarcity of high-quality datasets utilizing Magnifying Endoscopy with Narrow-Band Imaging (ME-NBI). Addressing this gap, we present EndoWLI-NBI, a large-scale dataset comprising 11,971 ME-NBI images from 868 patients, specifically curated to cover the full gastric precancerous cascade-including Intestinal Metaplasia & Chronic Gastritis, Low- and High-Grade Intraepithelial Neoplasia, and Early Gastric Cancer. Unlike existing public datasets, every image in EndoWLI-NBI is rigorously mapped to a biopsy-confirmed histopathological diagnosis, providing a definitive gold standard for label reliability. Technical validation using state-of-the-art deep learning benchmarks demonstrates the dataset's quality and separability, while highlighting the intrinsic visual challenges in distinguishing high-grade neoplasia from early cancer. This dataset serves as a critical, medically verified resource for advancing fine-grained lesion classification, domain adaptation research, and endoscopic training in gastroenterology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.